Atopic Dermatitis

A recent study highlights the need for ophthalmologic monitoring in pediatric dupilumab therapy.

The phase 1a study is a first in-human trial evaluating SYX-5219 for AD.

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis are particularly affected by social determinants of health, further impacting their outcomes.

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Experts discussed personalized approaches to atopic dermatitis, from steroid-sparing topicals to biologics, highlighting rapid relief and long-term management strategies.

Research suggests that rebalancing the skin microbiome with pre-, post-, and probiotics may improve AD symptoms.

Experts discussed pediatric atopic dermatitis, treatment innovations, disease burden, and the latest topical and systemic therapies in a DermView video series.

When compared to corticosteroids alone, the combination therapy reduced disease severity and improved the skin barrier.

APG990 showed a 60-day half-life and favorable safety, supporting potential 3-6 month maintenance dosing for atopic dermatitis.

At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.

Objective tools like IGA and EASI provide structured severity assessment but often lack patient-reported insights such as itch severity.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

A PDUFA target action date has been set for October 13, 2025.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a female patient aged 12 years with moderate AD that had been worsening over the past several months.

Lead author on recent research, Lawrence Eichenfield, MD, said if approved, this treatment could fill a “significant gap.”

The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a woman aged 25 years who presented with erythematous and scaly patches on her face, neck, and upper trunk.

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.